| Literature DB >> 16290276 |
Salomé Veiga1, Yunyun Yuan, Xuqin Li, Nuno C Santos, Gang Liu, Miguel A R B Castanho.
Abstract
The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells. Recent studies point out to a cell entry mechanism of this virus similar to other enveloped viruses, such as HIV-1. As it happens with other viruses peptidic fusion inhibitors, SARS-CoV S protein HR2-derived peptides are potential therapeutic drugs against the virus. It is believed that HR2 peptides block the six-helix bundle formation, a key structure in the viral fusion, by interacting with the HR1 region. It is a matter of discussion if the HIV-1 gp41 HR2-derived peptide T20 (enfuvirtide) could be a possible SARS-CoV inhibitor given the similarities between the two viruses. We tested the possibility of interaction between both T20 (HIV-1 gp41 HR2-derived peptide) and T-1249 with S protein HR1- and HR2-derived peptides. Our biophysical data show a significant interaction between a SARS-CoV HR1-derived peptide and T20. However, the interaction is only moderate (K(B)=(1.1+/-0.3)x10(5) M(-1)). This finding shows that the reasoning behind the hypothesis that T20, already approved for clinical application in AIDS treatment, could inhibit the fusion of SARS-CoV with target cells is correct but the effect may not be strong enough for application.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16290276 PMCID: PMC7116955 DOI: 10.1016/j.bbagen.2005.10.001
Source DB: PubMed Journal: Biochim Biophys Acta ISSN: 0006-3002
Sequences of HIV-1 fusion inhibitor peptides T20 and T-1249, and of the peptides derived from the HR1 and HR2 regions of SARS-CoV spike protein (Pep 1D, Pep 1E and Pep 2B, Pep HR2, respectively)
| Peptide | Protein location | Sequence |
|---|---|---|
| T20 | – | YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF |
| T-1249 | – | WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF |
| Pep 1D | 900–921 | ENQKQIANQFNKAISQIQESLT |
| Pep 1E | 931–951 | QDVVNQNAQALNTLVKQLSSN |
| Pep 2B | 1157–1178 | SVVNIQKEIDRLNEVAKNLNES |
| Pep HR2 | 1150–1189 | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE |
The corresponding amino acid residues in SARS-CoV S protein of the derived peptides used is in the table.
Fig. 1T20 (A) and T-1249 (B) fluorescence intensity variation in the presence of Pep 1D (●) and Pep 2B (▴). Small amounts of S peptides were added to a sample of T20 (10 μM) or T-1249 (6.7 μM).
Fig. 2ANS (26 μM) fluorescence intensity for the titration of (A) T20 with Pep 1D (and vice-versa), (B) T20 with Pep 2B (and vice-versa), (C) T-1249 with Pep 1D (and vice-versa) and (D) T-1249 with Pep 2B (and vice-versa). Small amounts of Pep 1D or Pep 2B were added to a T20 or T-1249 sample containing ANS, and vice-versa. T20 or T-1249 added to S peptide (♦) and S peptide added to T20 or T-1249 (●) lead to different results. Small amounts of each peptide (▴—T20 or T-1249; ▪—S peptide, Pep 1D in panel A and C and Pep 2B in panel B and D) were added to a buffer/ANS sample to evaluate self-aggregation.
Fig. 3Di-8-ANEPPS-labeled (10 μM) membranes (POPC 200 μM LUV) fluorescence difference spectra (λem = 603 nm). The spectra were obtained by subtracting the excitation spectrum before the addition of peptides from the excitation spectra after the peptides addition (15 μM). Before subtraction, the spectra were normalized to the integrated areas so that the difference spectra reflect only the spectral shifts. (A) T-1249, (B) T20 and (C) S peptides. The latter spectra have no meaningful difference among each other.
Fig. 4Partition plots of T20 (10 μM) to LUV of POPC. The experiments were done in the absence (●) and in the presence (▴) of equimolar S peptides Pep 1D (A) and Pep 2B (B).